MRK is testing MK-5172/MK-8742 in several specialized patient groups… • GT1 with chronic kidney disease: http://clinicaltrials.gov/ct2/show/NCT02092350 • GT1/4/6 with hepatic insufficiency: http://clinicaltrials.gov/ct2/show/NCT02115321 • GT1/4/6 with HIV co-infection: http://clinicaltrials.gov/ct2/show/NCT02105662 • GT1/4/6 with concurrent opiate-rehab therapy: http://clinicaltrials.gov/ct2/show/NCT02105688 • GT1/4/6 with sickle cell anemia, thalassemia, or hemophilia/von Willebrand disease (reposted from #msg-106755289): http://clinicaltrials.gov/ct2/show/NCT02252016 Don’t know what all this means, but it can’t be an encouraging sign for MRK’s 2-DAA regimen consisting of MK-5172 + MK-8742.